Enveric Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
ENVB$1.44+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| As of December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $2,241,026 | $2,287,977 |
| Prepaid expenses and other current assets | 493,558 | 1,293,554 |
| Total current assets | 2,734,584 | 3,581,531 |
| Other assets: | ||
| Property and equipment, net | 305,777 | 507,377 |
| Intangible assets, net | 42,182 | 210,932 |
| Total other assets | 347,959 | 718,309 |
| Total assets | $3,082,543 | $4,299,840 |
| LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $521,747 | $1,218,783 |
| Due to related parties | 232,891 | — |
| Accrued liabilities | 732,010 | 1,075,643 |
| Investment option liability | 1,988 | 23,608 |
| Warrant liability | 1,100 | 25,470 |
| Total current liabilities | 1,489,736 | 2,343,504 |
| Commitments and contingencies (Note 12) | - | - |
| Mezzanine equity | ||
| Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of December 31, 2024 and 2023, respectively | — | — |
| Redeemable non-controlling interest | — | — |
| Total mezzanine equity | — | — |
| Shareholders’ equity | ||
| Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of December 31, 2024 and 2023, respectively | — | — |
| Common stock, $0.01 par value, 100,000,000 shares authorized, 678,002 and 182,625 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 6,780 | 1,827 |
| Additional paid-in capital | 108,255,049 | 100,841,416 |
| Stock subscription receivable | — | (1,817,640) |
| Accumulated deficit | (106,074,505) | (96,499,518) |
| Accumulated other comprehensive loss | (594,517) | (569,749) |
| Total shareholders’ equity | 1,592,807 | 1,956,336 |
| Total liabilities, mezzanine equity, and shareholders’ equity | $3,082,543 | $4,299,840 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.